Analysts’ Weekly Ratings Changes for AbbVie (ABBV)

A number of firms have modified their ratings and price targets on shares of AbbVie (NYSE: ABBV) recently:

• 1/15/2026 – AbbVie had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 1/13/2026 – AbbVie had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 1/7/2026 – AbbVie is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $240.00 price target on the stock.
• 1/3/2026 – AbbVie was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/13/2025 – AbbVie was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – AbbVie had its price target raised by analysts at Morgan Stanley from $261.00 to $269.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – AbbVie was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $265.00 price target on the stock, up previously from $225.00.
• 12/10/2025 – AbbVie was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating.
• 11/30/2025 – AbbVie was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/22/2025 – AbbVie was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.